BY
en
  • Custom development &
    Manufacturing
    Custom development &
    Manufacturing
    • Custom development &
      Manufacturing
    • Custom APIs
    • Custom Intermediates
  • Generic
    APIs
  • Consumer Health
    Care
  • Drug Delivery
    Solutions
    Drug Delivery
    Solutions
    • Drug Delivery
      Solutions
    • Smart Excipients & Polymers Catalog
    • Custom Lipids
    • Custom GMP Polymers
  • Catalog
    Offer
    Catalog
    Offer
    • Catalog
      Offer
    • Product Catalog of Generic APIs
    • Pre-GMP API / Intermediates Catalog
    • Smart Excipients & Polymers Catalog
Locations Products
  • Seqens Group
  • Careers
  • Newsroom
  • Contact
  • Seqens Group
  • Careers
  • Newsroom
  • Contact
en
Products
Our locations
  • Custom development &
    Manufacturing
    Custom development &
    Manufacturing
    • Custom APIs
    • Custom Intermediates
  • Generic
    APIs
  • Consumer Health
    Care
  • Drug Delivery
    Solutions
    Drug Delivery
    Solutions
    • Smart Excipients & Polymers Catalog
    • Custom Lipids
    • Custom GMP Polymers
  • Catalog
    Offer
    Catalog
    Offer
    • Product Catalog of Generic APIs
    • Pre-GMP API / Intermediates Catalog
    • Smart Excipients & Polymers Catalog
Top of page
Share

Newsroom

Home Newsroom
API Manufacturing / General / Press Releases

IMPEKK™ for long term medical implants

08th november 2021

SEQENS renews its partnership and collaboration with Arkema for the development of its Medical IMPEKK™ PEKK for long-term implants, ideal for use in…

Read more
API Manufacturing / General / Press Releases 08th november 2021

IMPEKK™ for long term medical implants

SEQENS renews its partnership and collaboration with Arkema for the development of its Medical IMPEKK™ PEKK for long-term implants, ideal for use in…

Read more
General / Research and Development 07th may 2020

Flow chemistry for efficient and safe synthesis of APIs and intermediates

DOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…

Read more
API Manufacturing / General 24th february 2020

API lifecycle management: A CDMO perspective

Didier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…

Read more
API Manufacturing / General 06th february 2020

Developing Controlled Substances Requires a Whole New Level of Global Diligence

4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…

Read more
API Manufacturing / Articles / General 31st january 2020

The Growth of the Generic Drug Marketplace

The Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…

Read more
API Manufacturing / Articles / General / Research and Development 29th november 2019

Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs

Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.

Read more
API Manufacturing 28th october 2019

Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated…

Read more
Articles / General / Press Releases 14th september 2021

At the Helm of Seqens CDMO North America

I was privileged to work at Sanofi for 21 years, where I had the opportunity to be deeply involved in both technical and…

Read more
General 23rd november 2020

SEQENS is committed to the development and production of critical molecules in France

SEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate…

Read more
API Manufacturing / General 14th october 2020

A new large scale potent API manufacturing unit at SEQENS Villeneuve-La-Garenne

Shifting needs in the pharmaceutical market are driving a stronger demand for specialized production units to manufacture highly potent active…

Read more
General 03rd august 2020

Lahr’s Site: a Seqens CDMO plant.

Founded in 1991, The site of Lahr is part of SEQENS CDMO since mid-2015. The site is specialized in the development and manufacturing…

Read more
API Manufacturing / Articles / Press Releases / Research and Development 28th may 2020

What kind of chemical structure will help the control of the most life-threatening side effects associated with CoVid-19- Some Salicylamide derivatives appears to be able to compete

DOWNLOAD THE PRESS RELEASE Gérard Guillamot SEQENS Scientific Director Due to the urgency of finding a treatment against CoVid-19,…

Read more
API Manufacturing / General 18th may 2020

New warehouse for active ingredients (API’s) in Lahr

A new warehouse for active ingredients The production of active ingredients on site Lahr has increased steadily over the last years. It was…

Read more
API Manufacturing / Articles / General 19th february 2020

The CDMO’s Challenges Developing An Oral Suspension For Children

By, Didier Combis, Commercial Director, Seqens CDMO; Christine Adam, Business Development Manager, Unither Pharmaceuticals and Jean Francois Cordoliani, Site Director, Unither Développement Bordeaux…

Read more

Join theSeqens teams!

Find out more

Subscribe to our newsletter

  • Home
  • Newsroom
  • Privacy policy
  • GTC

About SEQENS

Contact us

Contact us

Follow the seqens evolution on

social media

DISCOVER OUR NEWS

Learn more